Dynavax Technologies Stock Price, News & Analysis (NASDAQ:DVAX)

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

Dynavax Technologies Co. (NASDAQ:DVAX) released its quarterly earnings results on Wednesday, August, 7th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.63) by $0.03. The biopharmaceutical company had revenue of $8.30 million for the quarter, compared to analysts' expectations of $8.24 million. Dynavax Technologies had a negative return on equity of 304.71% and a negative net margin of 781.10%. The firm's revenue for the quarter was up 564.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.63) earnings per share. View Dynavax Technologies' Earnings History.

Dynavax Technologies is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Dynavax Technologies.

4 equities research analysts have issued twelve-month price targets for Dynavax Technologies' shares. Their forecasts range from $13.00 to $30.00. On average, they anticipate Dynavax Technologies' share price to reach $21.00 in the next year. This suggests a possible upside of 358.5% from the stock's current price. View Analyst Price Targets for Dynavax Technologies.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dynavax Technologies.

News headlines about DVAX stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Dynavax Technologies earned a news sentiment score of -1.3 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Dynavax Technologies.

Some companies that are related to Dynavax Technologies include AnaptysBio (ANAB), Innoviva (INVA), Athenex (ATNX), Y-mAbs Therapeutics (YMAB), Spectrum Pharmaceuticals (SPPI), Zymeworks (ZYME), Epizyme (EPZM), Esperion Therapeutics (ESPR), Amphastar Pharmaceuticals (AMPH), Dicerna Pharmaceuticals (DRNA), ArQule (ARQL), Amneal Pharmaceuticals (AMRX), Axsome Therapeutics (AXSM), Cara Therapeutics (CARA) and NextCure (NXTC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Array Biopharma (ARRY), Kite Pharma (KITE), United Continental (UAL), Cara Therapeutics (CARA) and Micron Technology (MU).

Dynavax Technologies' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.01%), Senvest Management LLC (6.06%), Vanguard Group Inc. (5.53%), Chicago Capital LLC (4.51%), Eagle Asset Management Inc. (2.95%) and UBS Asset Management Americas Inc. (2.67%). Company insiders that own Dynavax Technologies stock include David F Novack, David Louis Johnson, Francis Cano, Michael S Ostrach and Robert Coffman. View Institutional Ownership Trends for Dynavax Technologies.

DVAX stock was sold by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., JPMorgan Chase & Co., Creative Planning, Bank of America Corp DE, A.R.T. Advisors LLC, Northern Trust Corp, Gables Capital Management Inc. and Bank of New York Mellon Corp. Company insiders that have sold Dynavax Technologies company stock in the last year include David Louis Johnson, Francis Cano, Michael S Ostrach and Robert Coffman. View Insider Buying and Selling for Dynavax Technologies.

DVAX stock was purchased by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, UBS Asset Management Americas Inc., Senvest Management LLC, Orbimed Advisors LLC, Point72 Asset Management L.P., C WorldWide Group Holding A S, Vanguard Group Inc. and Chicago Capital LLC. View Insider Buying and Selling for Dynavax Technologies.

Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DVAX stock can currently be purchased for approximately $4.58.

Dynavax Technologies has a market capitalization of $298.39 million and generates $8.20 million in revenue each year. The biopharmaceutical company earns $-158,900,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Dynavax Technologies employs 249 workers across the globe.View Additional Information About Dynavax Technologies.

The official website for Dynavax Technologies is http://www.dynavax.com/.

Dynavax Technologies' mailing address is 2100 Powell Street Suite 900, Emeryville CA, 94608. The biopharmaceutical company can be reached via phone at 510-848-5100 or via email at [email protected]